Enfuvirtide (T-20)
Ref. 3D-CRB1001408
| 1mg | Arrêté | ||
| 500µg | Arrêté |
Informations sur le produit
- Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2acetyl-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-amideacetyl-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu -Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn -Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Currently, enfuvirtide (T-20) is the only available membrane fusion inhibitor licensed for HIV-1 combination therapy. T-20 was designed to bind the HIV-1 gp41 peptide preventing viral formation and membrane fusion. The C-terminal tryptophan-rich motif (TRM) of T-20 is essential for target binding and inhibition of viral fusion. However, T-20 has a low genetic barrier for drug resistance and a short in vivo half-life. T-20 is used in combination therapy but has spawned huge interest in how to find more potent HIV-1 inhibitors in the future. T-20 can be used as a model peptide as some researchers have already tried with the aim to increase its clinical efficacy. T-20 is only effective against HIV-1, there is hope that further study of T-20 could provide more broad-spectrum antiviral peptides.
